Two international companies begin due diligence on Redwood Pharma’s product RP501 ahead of potential commercial agreements

Stockholm, May 7, 2024. Redwood Pharma AB (publ) announces today that two international companies have begun due diligence of the company’s unique and revolutionary product against dry eyes – RP501. Both companies have signed nondisclosure agreements to access Redwood Pharma’s virtual data room (VDR) to evaluate documentation prior to negotiations for potential commercial agreements.

Virtual data rooms are online platforms that contain confidential information about assets of commercial interest. Access to the data room is provided on a strictly confidential basis to potential partners for their evaluation of sensitive information including details of completed clinical studies and market research, intellectual property rights as well as discussions with regulatory authorities. Data rooms are crucial in an evaluation (due diligence) which in turn can lead to the signing of a commercial agreement.

“For some time now, we have had several parallel discussions with potential commercial partners who have shown great interest in the unique and revolutionary medical technology product RP501, and it is gratifying that two of these stakeholders have now chosen to sign confidentiality agreements. It gives them the opportunity to move forward in the process and carry out a thorough due diligence of the project,” says Martin Vidaeus, CEO of Redwood Pharma.

RP501 is being developed to be an effective and user-friendly over-the-counter thermogel for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The results of a clinical study show that RP501 is safe, provides a significant therapeutic effect already at a dosage of 1-2 drops per day and is convenient to use – characteristics that consumers consider the most important parameters for a dry eye product.

For reasons of confidentiality, Redwood Pharma is prevented from disclosing the names of the companies that have now begun the due diligence process of RP501. The company is in an early phase of a business process with the interested parties and that there are no guarantees that they will lead to final agreements.

For more information:

Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29

About Redwood Pharma

Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today’s standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma’s programs are based on IntelliGel – a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, For more information, visit